48 results about "Hepatitis b core" patented technology

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.

The invention discloses a fluorescent microsphere immunochromatographic testing card for testing five indexes of hepatitis b and a method for preparing the same. The testing card comprises a hepatitis b surface antigen test paper strip, a hepatitis b e surface antigen test paper strip, a hepatitis b surface antibody test paper strip, a hepatitis b e surface antibody test paper strip, and a hepatitis b core antibody test paper strip. Each test paper strip is formed by overlapping and bonding filter paper, a sample pad, a glass fiber film spray-coated with fluorescent microspheres, a cellulose nitrate film and water absorption paper on a bottom plate by glue in sequence, wherein the cellulose nitrate film is coated with antigens serving as a testing area and anti-rabbit antibodies serving as a quality control area; and during a test, after emitted fluorescent light passes a filter, the emitted spectrum is collected, accumulated and multiplied by the CCD scanning technology and then converted into a numerical signal, the numerical signal is multiplied by a correction factor, and the strength of the corrected fluorescent light is substituted in a standard curve of a fluorescence analyzer, so that the concentrations of the five indexes of hepatitis b of the sample can be automatically worked out. The test of hepatitis b viruses by the testing card has the characteristics of specificity, sensitivity, simpleness and accuracy.

The invention provides a chemoluminescence immunoassay measuring kit and a preparation method thereof for hepatitis B core antibody magnetic particles. The kit comprises a hepatitis B core antibody calibration sample, magnetic particles coated by a hepatitis B core antigen, an enzyme marker, a chemoluminescence substrate and a concentrated washing solution. The invention effectively utilizes a magnetic particle solid separation system and a chemoluminescence immunoassay technology to detect the hepatitis B core antibody. The kit has the advantages of simple and fast detection, high sensitivity, strong specificity, stability, and the like, can well satisfy the requirement of clinic diagnosis and is suitable to be effectively generalized and applied in industry.

The invention discloses a therapeutic hepatitis B vaccine. Active components of the therapeutic hepatitis B vaccine comprise a protein gp96, a hepatitis B surface antigen and a hepatitis B core protein. The protein gp96 has a sequence shown in the sequence 1 of the sequence table. The hepatitis B surface antigen has a sequence shown in the sequence 5 of the sequence table. The hepatitis B core protein has a sequence shown in the sequence 3 of the sequence table. The active components also comprise a plasmid pcDNA-gp96 containing a coding gene of the protein gp96, a plasmid pcDNA-HB containing a coding gene of the hepatitis B surface antigen and a plasmid pcDNA-HBc containing a coding gene of the hepatitis B core protein. The therapeutic hepatitis B vaccine provided by the invention can effectively inhibit hepatitis B virus (HBV) replication, can eliminate viruses infecting the liver and has a very important value to hepatitis B prevention and treatment.

The invention discloses fusion protein of divisive ranilla luciferase and HBC (hepatitis B core). The fusion protein is obtained by joint connection of 1 to 229 amino acids of the N-terminal of the ranilla luciferase and core protein of hepatitis B virus (HBV), or obtained by joint connection of 229 to 311 amino acids of the N-terminal of the ranilla luciferase and the core protein of the HBV, the sequence of the amino acids is as shown in SEQ (sequence) ID (identity) No: 1 and No: 3 respectively, and nucleotide sequence encoding the two fusion protein is as shown in SEQ ID No: 2 and No: 4 respectively. The invention further discloses a carrier containing the nucleotide sequence as is shown in the SEQ ID No: 2 and No: 4. and discloses an application about whether the fusion protein as is shown in the SEQ ID No: 1 or the No: 3 is formed or not in indication of core protein dimers of the HBV. An importation foundation is laid for establishing cell models for drug screening in formation of the anti-HBC dimers.

The disclosed dual-sandwich enzyme-linked immunologic diagnosis agent box for hepatitis-B core antibody comprises: a micro-porous reaction plate composed by the hepatitis-B core antigen recombinant with purity more than 90% and 5*104~5*105u/mg titer, and the enzyme compound composed by the hepatitis-B core antigen recombinant marked by HRP. This invention has high specificity and sensitivity and convenient to qualitative or semi-qualitative detection.

The invention discloses an application of lindley eupatorium herb in preparing anti-hepatitis B virus medicaments. Lindley eupatorium herb ethanol extract, lindley eupatorium herb flavone part, lindley eupatorium herb hemiterpene part, lindley eupatorium herb 70% ethanol water elution part and chain diterpene are prepared from lindley eupatorium herb and are subjected to hepatitis B virus (HBV) testing, and testing results indicate that the four extracts and the chain diterpene have the effect of remarkably inhibiting hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBeAg), and have better drug activities than those of clinical medicament lamivudine (3TC) for treating hepatitis B. The lindley eupatorium herb can be used for preparing medicaments for resisting hepatitis B virus.

The invention relates to one or more types of recombinant fusion proteins formed by hepatitis B core proteins and mycobacterium tuberculosis antigens or antigen fragments. The tuberculosis antigens or antigen fragments are inserted in the same or different permission sites of hepatitis B core proteins in a mode of single antigen or antigen fragment or various types of antigens or antigen fragments which are combined together. The recombinant fusion proteins may comprise a plurality of cofactors. In addition, the invention also relates to the type of the fusion of the tuberculosis antigen or antigen fragments and cofactors and hepatitis B core proteins, nucleic acid and amino acid sequences of coded corresponding recombinant fusion proteins, a method for preparing the recombinant fusion proteins and application of the recombinant fusion proteins in the preparation of medicaments and vaccines for preventing and/or treating tuberculosis.

The invention provides a CXCL13 (chemokine(C-X-C motif) ligand 13) DNA vaccine and an application thereof. According to the CXCL13 DNA vaccine, overall-length cDNA of CXCL13 and HBc (Hepatitis B core) are connected, and a vector is pcDNA 3.1(-). A tumor targeted drug prepared from the CXCL13 DNA vaccine generates stronger humoral immunity response by stimulating an active immunity system of an organism and can inhibit p-AKT, p-ERK and EMT signal pathways, thereby inhibiting tumor cell growth as well as invasion and metastasis and realizing the anti-tumor effect.

A gene engineering vaccine for preventing pig cysticercosis and its preparation process are disclosed. The process includes the steps: making the hepatitis B virus core protein as carrier, inserting cysticercus cellulosae protective antigen gene in multiple locations between the first amino acid to No. 183 amino acid hepatitis B core protein, cloning to procaryon expression plasmid or eucaryon expression plasmid, transforming host bacteria, expressing by inducing aim gene and acquiring aim protein or column purified eucaryon expression plasmid DNA therefore, subunit protein vaccine or nucleic acid vaccine for preventing pig cysticercosis are obtained.

The invention discloses a CTGF (connective tissue growth factor) chimeric vaccine for treating liver fibrosis. The antigenic epitope of the CTGF is inserted into c/e1B cell epitope of hepatitis b virus core antigen to form the CTGF chimeric vaccine which can be assembled into hepatitis B core sample particles. Under the non-adjuvant assistance, the chimeric vaccine can stimulate a body to generate high-valence anti-CTGF neutral antibody. A mouse which is immunized by the chimeric vaccine is obviously relieved in fibrosis degree generated after carbon tetrachloride induction. According to the experimental verification, the CTGF chimeric vaccine can be used for obviously restraining the activation intensity of hepatic stellate cells in the mouse liver, and also can be used for stimulating liver cells to multiply and restraining liver apoptosis. Besides, the TGF-beta 1 and PDGF level in the immunized mouse is obviously reduced, so that the process of liver fibrosis can be relieved in a facilitated manner. According to the results, the CTGF chimeric vaccine can be used for successfully restraining the carbon-tetrachloride-induced mouse liver fibrosis. Therefore, the CTGF chimeric vaccine is expected to be developed into effective means for treating the liver fibrosis.

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating HepatitisB (HBV) infection.

The invention relates to a recombinant plasmid DNA vaccine composition for treating Hepatitis B. The composition contains a recombinant vaccine plasmid which simultaneously carries Hepatitis B middle protein S2S coding gene and Hepatitis B Core protein coding gene as well as a recombinant adjuvant plasmid, wherein the adjuvant plasmid is the adjuvant plasmid of recombinant interleukin 2 or recombinant human interferon gamma.

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitisB, comprising administering to a patient in need thereof a disclosed compound of formula:

The invention belongs to the field of molecular immunity and relates to an aptamer sequence for a hepatitis B virus (HBV) core antigen and an application of the nucleic aptamer sequence. According to the invention, a gene-recombination plasmid is adopted to express the core antigen, and an aptamer specially bound with the core antigen is screened, so as to prepare a characteristic sequence CATTT with the special binding HBV core antigen. The characteristic sequence is the base of the special binding of the aptamer and the HBc (hepatitis B core) antigen, can be used for drug design and the preparation of drugs and other products; and the aptamer with the characteristic sequence can be used as a probe or therapeutic target resisting to HBV to design and prepare drugs or agents resisting to HBV.

The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitisB, comprising administering to a patient in need thereof a disclosed compound.

The invention discloses nanoparticles with an AIAE (aggregation-induced absorption enhancement) phenomenon as well as synthesis and an application of the nanoparticles and relates to nanoparticles. The nanoparticles with the AIAE phenomenon comprise inner cores and outer layers, wherein the inner cores are croconaine analogues, the outer layers are protein particles, the inner cores are loaded ininner cavities of the outer layers, and composite nanostructures with the croconaine analogues as the inner cores and the protein particles as the outer layers are formed. Hepatitis B core protein particles are diluted and added to a depolymerization buffer solution to be stirred; dye is uniformly stirred in DMSO, and croconaine analogue dye is obtained; the croconaine analogue dye is added to anobtained mixture and stirred, and a mixed liquid is obtained; the mixed liquid is added to a dialysis bag, dialysis is performed in an assembling buffer solution 1, and a magnetic stirring reaction isperformed; the mixed liquid is added to the dialysis bag, dialysis is performed in an assembling buffer solution 2, and a magnetic stirring reaction is performed to obtain medicine-carrying protein nanoparticles; the obtained medicine-carrying protein nanoparticles are subjected to <125>I labeling, and the nanoparticles with the AIAE phenomenon are obtained.

The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analogue anti-HBV drug), and thus guide the patients to reasonably choose drugs.

A nucleic acid vaccine for preventing and treating atherosolerosis and its preparing process are disclosed. The core protein of hepatitis B is used as its immune carrier to intensify the immunogenicity of CETPC. The body immunized by said vaccine can generate CETPC antibody to suppress the activity of cholesteryl ester transfer protein, so decreasing the generation of atherosclerosis spots. It can also act on the formed atherosclerosis sports to relay them.